Aptevo Therapeutics competitors

Jeff Albers is the chief executive officer of [Blueprint Medicines](https://www.crunchbase.com/organization/blueprint-medicines), a company engaged in the discovery and development of highly selective kinase inhibitors for genomically defined cancer subsets. He was previously the president of Algeta. Prior to Algeta, he served at Genzyme, where he spent seven years in senior commercial and corporate development positions. Before joining Genzyme, he spent five years as an Attorney at the law firm Mintz Levin Cohn Ferris Glovsky & Popeo. He also has prior experience as a sales representative for Pfizer. Albers holds a bachelor’s degree in marketing from Indiana University and an MBA from Georgetown University.

Shai Gozani, founded NeuroMetrix, Inc. in 1996 as a spin-off from the Massachusetts Institute of Technology. He currently serves as Chairman of the board of directors and as our President and Chief Executive Officer. Shai has led the Company from a venture capital backed start-up, through an initial public offering on Nasdaq, through development of a successful diagnostics business, and presently into the wearable technology sector. Over 2.5 million patients have benefited from the Company’s technology over the past 17 years.Shai has published over 30 peer-reviewed scientific articles and has been awarded over 40 US and international patents. He holds a B.A. degree in Computer Science, a M.S. degree in Electrical Engineering & Computer Science (Biomedical Engineering Focus) and a Ph.D. in Neurobiology, from the University of California, Berkeley. Shai also received an M.D. from Harvard Medical School and the Harvard-MIT Division of Health Sciences and Technology at M.I.T.